Combining Immunotherapy for Glioblastoma patents related to PEP-CMV DC vaccine with tetanus, as well as poliovirus vaccine and D2C7 in the treatment of glioblastoma. JHS has an equity interest in Annias Immunotherapeutics, which has licensed intellectual property from Duke related to the use of the pepCMV vaccine in the treatment of glioblastoma. 18. JS reports research funding to his institution from Bayer, Roche, Bristol Myers Squiib, Abbvie, Astra Zeneca, MSD, AbbVie and Astellas. 19. DB is co-owner of Berry Consultants, LLC, a company that designs adaptive Bayesian clinical trials for pharmaceutical and medical device companies, NIH cooperative groups, patient advocacy groups, and international consortia. 20. GZ reports no conflicts of interest. 21. TFC is a co-inventor on patent 62/819,322 licensed to Katmai Pharmaceuticals and a Member of the board for the 501c3 Global Coalition for Adaptive Research. 22. MPM reports consultant or advisory roles for Zap, Mevion, Karyopharm, Tocagen and Astra-Zeneca; and Board of Directors options from Oncoceutics. 23. SPreports consultant or advisory roles for Syntalogic, the MITRE Corporation, and Omnitura. 24. MW has received research grants from AbbVie, Adastra, BMS, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Quercis, and Roche; and honoraria for lectures or advisory board participation or consulting from AbbVie, BMS, Celgene, MSD, Merck (EMD), Novocure, Orbus, Roche, and Tocagen. 25. ABH reports consultant or advisory roles for Caris Life Sciences and WCG Oncology; royalties on licensed intellectual property from Celldex Therapeutics and DNAtrix; research funding from Celularity, Carthera, Codiak, and Moleculin. 26. MK reports consultant or advisory roles for Janssen,